KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Revenue: 2020-2025

Historic Revenue for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to $5.2 million.

  • Recursion Pharmaceuticals' Revenue fell 80.16% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.7 million, marking a year-over-year decrease of 32.98%. This contributed to the annual value of $58.8 million for FY2024, which is 32.00% up from last year.
  • Recursion Pharmaceuticals' Revenue amounted to $5.2 million in Q3 2025, which was down 73.08% from $19.2 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' Revenue's 5-year high stood at $26.1 million during Q3 2024, with a 5-year trough of $2.5 million in Q4 2021.
  • Its 3-year average for Revenue is $13.0 million, with a median of $12.1 million in 2023.
  • In the last 5 years, Recursion Pharmaceuticals' Revenue surged by 4,170.00% in 2021 and then crashed by 80.16% in 2025.
  • Quarterly analysis of 5 years shows Recursion Pharmaceuticals' Revenue stood at $2.5 million in 2021, then surged by 439.91% to $13.7 million in 2022, then declined by 20.36% to $10.9 million in 2023, then crashed by 58.26% to $4.5 million in 2024, then plummeted by 80.16% to $5.2 million in 2025.
  • Its last three reported values are $5.2 million in Q3 2025, $19.2 million for Q2 2025, and $14.7 million during Q1 2025.